Pyxis Oncology reports 39% confirmed response rate for MICVO in Phase 1 head and neck cancer trial
PYXS•Pyxis Oncology reported a 39% confirmed response rate for MICVO in a Phase 1 trial for previously treated recurrent or metastatic head and neck cancer. The company plans to start a global Phase 3 trial in mid-2027.
1. Phase 1 results
Pyxis Oncology reported updated Phase 1 results showing durable responses to MICVO in previously treated recurrent or metastatic head and neck cancer, with a 39% confirmed response rate. The company said clinical activity was consistent across patient subgroups and the safety profile was manageable.
2. Next steps
Pyxis Oncology said the findings support plans to initiate the global Phase 3 Headliner trial in mid-2027. Results will be presented November 19, 2026, at the EORTC-NCI-AACR Symposium in Barcelona.




